ValenToBiotics/ValenToBioScience has launched an offensive on the European greenhouse tomato market by recently unveiling ‘Matias,’ a new variety designed to combat Tomato Brown Rugose Fruit Virus (ToBRFV). For the past few years, ToBRFV has been identified as one of the most sensitive tomato disease issues in major production regions such as Europe, the Middle East, and North America, and the possession of disease resistance has emerged as a key criterion for the adoption of commercial varieties.
According to the company's announcement, Matias is a variety developed to target the specialized cultivation market based on its resistance to ToBRFV. It was presented as a key feature that prioritizes disease resistance while simultaneously considering fruit shape, yield, and suitability for distribution. In particular, as the demand for alternative varieties is rapidly increasing in regions where the cultivation stability of existing flagship varieties has been shaken following the spread of the virus, industry attention is focused on the speed of new variety introduction.
From a Korean perspective, this announcement is interpreted as more than just the launch of a new overseas variety; it serves as an example demonstrating that the competitive axis of the global tomato seed market is shifting from "high yield" to "combined disease resistance + marketability." Given that greenhouse tomato cultivation in Korea places great importance on disease management costs and seed selection, the expansion of ToBRFV-resistant lines verified in overseas markets is likely to have a significant impact on future import seed portfolios and breeding directions.
The industry anticipates that ToBRFV-resistant tomatoes will continue to grow rapidly, driven by international exhibitions, variety catalogs, and cultivation trials. In the actual market, final adoption is determined not merely by the possession of resistance, but also by adaptability to the growing season, fruit uniformity, storability and transportability, and the ability to meet specifications preferred by trading partners. Accordingly, the success of Matias in the market is expected to hinge on how stably it implements the commercial traits required in actual distribution, along with disease resistance.
Sources